Mersana Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Mersana Therapeutics

09/05/2023 14:31

* Mersana Therapeutics Inc  MRSN.OQ  reported a quarterly
adjusted
loss of 52 cents​​ per share for the quarter ended in March. The
mean expectation of eight analysts for the quarter was for a
loss of 44 cents per share.
    * Revenue rose 283.2% to $7.80 million from a year ago;
analysts
expected $18.29 million. 
    * Mersana Therapeutics Inc's reported EPS for the quarter
was a
loss of 52 cents​.
    * The mean earnings estimate of analysts had risen by
about 20.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Mersana Therapeutics Inc shares had risen by 80.5% this
quarter and gained 26.6% so far this year.
    * The company reported a quarterly loss of $56.16 million.
    * Wall Street's median 12-month price target for Mersana
Therapeutics Inc is $14.50 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 8 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
9 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.44          -0.52          Missed
 Dec. 31 2022      -0.50          -0.44          Beat
 Sep. 30 2022      -0.09          -0.61          Missed
 Jun. 30 2022      -0.52          -0.55          Missed